Northann names Vincent La Scala to board, taps him as audit committee chair
Bitget2026/10/07 21:15Northann elected Vincent La Scala to its board on Oct. 5, 2026, filling the vacancy created by Umesh Patel’s resignation. La Scala will chair the audit committee. He will join the nomination committee and compensation committee. He spent more than 30 years at Citigroup, most recently as Director, Independent Commercial Risk Management through April 2023. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northann Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001575872-26-000679), on October 07, 2026, and is solely responsible for the information contained therein.
- Northann elected Vincent La Scala to its board on Oct. 5, 2026, filling the vacancy created by Umesh Patel’s resignation.
- La Scala will chair the audit committee. He will join the nomination committee and compensation committee.
- He spent more than 30 years at Citigroup, most recently as Director, Independent Commercial Risk Management through April 2023.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The battle for customer loyalty heats up ahead of the holiday season! Walmart (WMT.US) launches a $120 membership package, going head-to-head with Amazon Prime and Costco.
Walmart launched a joint membership package for Walmart+ and Sam’s Club Plus this week, directly competing with Amazon Prime and Costco.
Data: ETH falls below 2,300 USD
Survival period doubled! AstraZeneca's new stomach cancer drug Sone-ve aims for $5 billion in annual sales, ADC takes another step towards replacing chemotherapy
AstraZeneca's gastric cancer ADC doubles patient survival, extending life by five more months, aiming for annual sales of $5 billion; the company is racing with Takeda and Astellas to target Claudin 18.2.
16 trillion Korean won "big dividend"! SK hynix (SKHY.US) plans to distribute 80% of Kioxia stake earnings generously to shareholders
According to reports, SK Hynix plans to return about 80% of the proceeds from reducing its stake in Japan's Kioxia Holdings to shareholders by distributing a special dividend of approximately 16 trillion won (about $12 billion).
Crypto prices
More
